Ascendis Pharma A (ASND) Return on Capital Employed (2015 - 2026)
Ascendis Pharma A (ASND) reported Return on Capital Employed of 1.07% for Q1 2026, down 3128135.0% on a YoY basis from N/an in Q1 2025, and up 98.62% sequentially from 77.11% in Q4 2025.
Ascendis Pharma A (ASND) Return on Capital Employed (2015 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 12 years of Return on Capital Employed data on file, last reported at 1.07% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3128135.0% year-over-year to 1.07%; the trailing twelve-month figure through Mar 2026 stood at 1.07% (down 3128135.0% YoY), and the FY2025 full-year result was 13.05%, up 932.0% from the prior year.
- Return on Capital Employed climbed to 1.07% in Q1 2026, from 77.11% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 353792.71% in Q2 2025 to a low of 3250.34% in Q1 2024.
- A 5-year average of 41538.82% and a median of 47.24% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 35323588 bps in 2025 and sank 3128135 bps in 2026, its largest moves.
- Tracing ASND's Return on Capital Employed over 5 years: stood at 57.78% in 2022, then sank by 572 bps to 388.46% in 2023, then surged by 7159 bps to 27420.7% in 2024, then sank by 100 bps to 77.11% in 2025, then surged by 99 bps to 1.07% in 2026.
- Business Quant data shows ASND's Return on Capital Employed at 1.07% in Q1 2026, 77.11% in Q4 2025, and 297625.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Ascendis Pharma A | 15.35 Bn | 14.68 Bn | 268.20 Mn | -1.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.07% |
| Dec 31, 2025 | -77.11% |
| Sep 30, 2025 | 297,625.78% |
| Jun 30, 2025 | 353,792.71% |
| Mar 31, 2025 | 31,280.29% |
| Dec 31, 2024 | 27,420.70% |
| Sep 30, 2024 | -388.80% |
| Jun 30, 2024 | 556.83% |
| Mar 31, 2024 | -3,250.34% |
| Dec 31, 2023 | -388.46% |
| Sep 30, 2023 | -87.29% |
| Jun 30, 2023 | -79.67% |
| Mar 31, 2023 | -69.84% |
| Dec 31, 2022 | -57.78% |
| Sep 30, 2022 | -47.24% |
| Jun 30, 2022 | -39.63% |
| Mar 31, 2022 | -29.22% |
| Dec 31, 2021 | -30.52% |
| Sep 30, 2021 | -47.89% |
| Jun 30, 2021 | -49.30% |